Drugs / Adibelimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06336954 | Mar → Jul 2024 overdue | non-small cell lung carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adibelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06336954 ↗ |
| Modality | Monoclonal antibody | “Adibelimab monoclonal antibody” NCT06336954 ↗ |
| Route | Intravenous | “Adibelimab (1200mg, IV, every 3 weeks)” NCT06336954 ↗ |